Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,636 1,716 1,764 1,774 1,733 1,595
Vimpat 1,099 1,302 1,422 1,524 1,333 879 695
Keppra  790 760 733 687 626 577 534
Briviact 142 229 307 385 451 510 555
Neupro 321 331 328 288 233 197 178
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab) 115   254  390  510 625  724
Midazolam nasal spray 8 23  40  60  77  89
Bimekizumab 63  173  328   482
Rozanolixizumab (Rozimab/Roza)  40 118  228 
Padsevonil 29  90   167
Anti-Tau  0  0  0  50 125

  *in the next 5 years

UCB FY Consensus Earnings Estimates (Average)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,673 5,008  5,257
Revenue  4,632 4,865 5,193 5,435
Recurring EBIT 1,105  1,112 1,167 1,302
Recurring EBITDA 1,398  1,397 1,468 1,623
Net Profit*  800 832 848 961
Core EPS (€) 4.78  4.87 5.05 5.64

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,628 1,686 1,705 1,715 1,667 1,606
Vimpat 1,099 1,299 1,425 1,519 1,354 907 743
Keppra 790 751 731 675 632 595 559
Briviact 142 230 305 387 455 511 555
Neupro 321 331 325 275 214 184 160
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab) 130 315 450 600 700 775 
Midazolam nasal spray 8 24  43  64   82 100
Bimekizumab  0 52  166  335  524 
Rozanolixizumab (Rozimab/Roza)  0 30  95  203
Padsevonil  78  151
Anti-Tau  0  0 50  125 

 *in the next 5 years

UCB FY Consensus Earnings Estimates (Median)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,666 4,992  5,234 
Revenue  4,632 4,871 5,133 5,349
Recurring EBIT 1,105  1,112 1,159 1,290
Recurring EBITDA  1,398 1,405 1,440 1,621
Net Profit*  800  813 823 945
Core EPS (€)  4.78 4.85 4.88 5.63

*attributable to UCB shareholders

Downloads:
UCB FY 2019 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 11 February, 2020



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.